Literature DB >> 11356794

Systemic and lung physiological changes in rats after intravascular activation of complement.

J G Younger1, N Sasaki, J Delgado, A C Ko, T X Nghiem, M D Waite, G O Till, P A Ward.   

Abstract

Systemic complement activation has been noted in a variety of shock states, and there is growing evidence that, in addition to being proinflammatory effectors, products of complement activation contribute directly to generalized manifestations of shock, such as hypotension and acidosis. To study the effects of complement activation, we examined responses in rats to systemic activation of complement with cobra venom factor (CVF), including blood pressure, metabolic acidosis, changes in vascular permeability, and lung function. High doses of CVF produced circulatory collapse (mean arterial pressure = 110 +/- 16 and 35 +/- 9 mmHg in control and with CVF, respectively, P < 0.05), metabolic acidosis (HCO concentration = 27.8 +/- 1.7 and 9.6 +/- 3.4 meq/l in control and with CVF, respectively, P < 0.05), extravasation of albumin into the lung and gut, and modest arterial hypoxemia (PO2 = 486 +/- 51 and 201 +/- 36 Torr in control and during 100% O2 breathing, respectively, P < 0.05). Prior depletion of complement protected against these abnormalities. Other interventions, including neutrophil depletion and cyclooxygenase inhibition, prevented lung injury but had much less effect on systemic hemodynamics or gut permeability, suggesting that complement activation products induce injury by neutrophil- and cyclooxygenase-dependent pathways in the lung but not in the gut. These studies underscore the significant systemic abnormalities developing after systemic activation of complement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356794     DOI: 10.1152/jappl.2001.90.6.2289

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  10 in total

1.  Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis.

Authors:  I J Messias-Reason; S Y Hayashi; R M Nisihara; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 2.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

3.  Complement C5 and early oxygen kinetics during murine sepsis.

Authors:  Gabriel Valencia; J Vidya Sarma; John G Younger
Journal:  Acad Emerg Med       Date:  2005-04       Impact factor: 3.451

4.  Complement activation in emergency department patients with severe sepsis.

Authors:  John G Younger; David O Bracho; Hangyul M Chung-Esaki; Moonseok Lee; Gurpreet K Rana; Ananda Sen; Alan E Jones
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

5.  Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Authors:  Erin C Conrad; Yueh-Ya Hsu; David M Bortz; John G Younger
Journal:  J Innate Immun       Date:  2013-01-11       Impact factor: 7.349

6.  Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury.

Authors:  Wei Jiang; Sean R Hall; Michael P W Moos; Richard Yang Cao; Satoshi Ishii; Kofo O Ogunyankin; Luis G Melo; Colin D Funk
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

7.  Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia.

Authors:  John G Younger; Sunita Shankar-Sinha; Marc Mickiewicz; Adam S Brinkman; Gabriel A Valencia; J Vidya Sarma; Ellen M Younkin; Theodore J Standiford; Firas S Zetoune; Peter A Ward
Journal:  Am J Respir Cell Mol Biol       Date:  2003-10       Impact factor: 6.914

Review 8.  Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability.

Authors:  Matthew R DiStasi; Klaus Ley
Journal:  Trends Immunol       Date:  2009-09-23       Impact factor: 16.687

9.  Pathways to acute humoral rejection.

Authors:  Soheyla Saadi; Takao Takahashi; Robert A Holzknecht; Jeffrey L Platt
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  Pretreatment with atorvastatin ameliorates cobra venom factor-induced acute lung inflammation in mice.

Authors:  Jing Guo; Min Li; Yi Yang; Lin Zhang; Li-Wei Zhang; Qian-Yun Sun
Journal:  BMC Pulm Med       Date:  2020-10-12       Impact factor: 3.317

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.